Patient Care Online: FDA Clears IND for Alphyn’s Zabalafin Hydrogel for Atopic Dermatitis
by Patient Care Editorial Staff
The US Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application submitted by Alphyn Biologics for Zabalafin Hydrogel, a topical therapy intended for the treatment of mild to moderate atopic dermatitis (AD).
CONTACTS
Corporate:
Neal Koller
nkoller@alphynbiologics.com
(410) 690-8687
Media:
Susan Thomas
susan@endpointcommunications.net
(619) 540-9195